The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

This study is testing whether tranexamic acid — a medication typically used to reduce bleeding — can also help fade skin discoloration caused by lichen planus pigmentosus (LPP), erythema dyschromicum perstans (EDP), or ashy dermatosis (AD). These are conditions where patches of gray-brown pigmentation develop on the skin, often affecting the face, neck, and trunk. The discoloration can be long-lasting and difficult to treat, causing significant distress. Transexamic acid has been found to reduce melanin production in the skin in some studies. This trial tests whether oral or topical tranexamic acid can reduce the intensity of pigmentation in these conditions, helping to fade the dark patches. You may be eligible if: - You are 18 years or older - You have a confirmed diagnosis of LPP, EDP, or ashy dermatosis - You have stopped all topical or oral treatments for pigmentary abnormalities (except sunscreen) at least one month before the study You may NOT be eligible if: - You have a personal history of blood clotting disorders or a thromboembolic event (deep vein thrombosis, stroke, etc.) - You have active cancer (excluding non-melanoma skin cancer) - You have moderate to severe kidney impairment - You have a history of migraines with aura - You are on anticoagulant therapy or hormonal contraception or hormone replacement therapy within the past 30 days - You are pregnant, breastfeeding, or planning to become pregnant Talk to your doctor to see if this trial is right for you.